404 related articles for article (PubMed ID: 24002547)
1. Establishment and characterization of a paclitaxel‑resistant human esophageal carcinoma cell line.
Wang C; Guo LB; Ma JY; Li YM; Liu HM
Int J Oncol; 2013 Nov; 43(5):1607-17. PubMed ID: 24002547
[TBL] [Abstract][Full Text] [Related]
2. Anti-proliferative effect of Jesridonin on paclitaxel-resistant EC109 human esophageal carcinoma cells.
Wang C; Guo L; Wang S; Wang J; Li Y; Dou Y; Wang R; Shi H; Ke Y; Liu H
Int J Mol Med; 2017 Mar; 39(3):645-653. PubMed ID: 28204832
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
[TBL] [Abstract][Full Text] [Related]
4. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line.
Wen J; Zheng B; Hu Y; Zhang X; Yang H; Luo KJ; Zhang X; Li YF; Fu JH
Oncol Rep; 2009 Jul; 22(1):65-71. PubMed ID: 19513506
[TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of a paclitaxel-resistant human gastric carcinoma cell line.
Fu L; Yin F; Li XR; Han BK; Zhang C; Wang JW; Wang YQ; Bi YF; Liu HM
Anticancer Drugs; 2018 Jul; 29(6):491-502. PubMed ID: 29683800
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Bcl-2 family and P-glycoprotein reverses paclitaxel resistance in human esophageal carcinoma cell line.
Shi X; Dou Y; Zhou K; Huo J; Yang T; Qin T; Liu W; Wang S; Yang D; Chang L; Wang C
Biomed Pharmacother; 2017 Jun; 90():897-905. PubMed ID: 28441715
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-loaded N-octyl-O-sulfate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance.
Jin X; Mo R; Ding Y; Zheng W; Zhang C
Mol Pharm; 2014 Jan; 11(1):145-57. PubMed ID: 24261922
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of taxol in human head and neck tumors.
Gan Y; Wientjes MG; Schuller DE; Au JL
Cancer Res; 1996 May; 56(9):2086-93. PubMed ID: 8616855
[TBL] [Abstract][Full Text] [Related]
10. [Cisplatin induces drug resistance in human esophageal squamous carcinoma cell line EC109 by decreasing CTR1 protein expression].
Yu L; Chen MH; Gu CP; Li YL; Wen J; Fu JH; Cho CH; Liu SW
Nan Fang Yi Ke Da Xue Xue Bao; 2011 May; 31(5):801-4. PubMed ID: 21602128
[TBL] [Abstract][Full Text] [Related]
11. A novel approach to overcome multidrug resistance: utilization of P-gp mediated efflux of paclitaxel to attack neighboring vascular endothelial cells in tumors.
Yoshizawa Y; Ogawara K; Kimura T; Higaki K
Eur J Pharm Sci; 2014 Oct; 62():274-80. PubMed ID: 24956463
[TBL] [Abstract][Full Text] [Related]
12. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells.
Sato S; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Iba T; Naniwa J; Uegaki K; Terakawa N
Cancer Chemother Pharmacol; 2004 Mar; 53(3):247-52. PubMed ID: 14610615
[TBL] [Abstract][Full Text] [Related]
13. [Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo].
Ji YB; Zhou JH; Zuo MX; You QD
Yao Xue Xue Bao; 2008 Aug; 43(8):811-8. PubMed ID: 18956773
[TBL] [Abstract][Full Text] [Related]
14. Insights into anticancer activity and mechanism of action of a ruthenium(II) complex in human esophageal squamous carcinoma EC109 cells.
Guo L; Lv G; Qiu L; Yang H; Zhang L; Yu H; Zou M; Lin J
Eur J Pharmacol; 2016 Sep; 786():60-71. PubMed ID: 27262377
[TBL] [Abstract][Full Text] [Related]
15. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
16. RFT2 is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenesis by sustaining cell proliferation and protecting against cell death.
Jiang XR; Yu XY; Fan JH; Guo L; Zhu C; Jiang W; Lu SH
Cancer Lett; 2014 Oct; 353(1):78-86. PubMed ID: 25045844
[TBL] [Abstract][Full Text] [Related]
17. Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo.
Chen SY; Hu SS; Dong Q; Cai JX; Zhang WP; Sun JY; Wang TT; Xie J; He HR; Xing JF; Lu J; Dong YL
Asian Pac J Cancer Prev; 2013; 14(10):6135-40. PubMed ID: 24289639
[TBL] [Abstract][Full Text] [Related]
18. Dexamethasone inhibits the effect of paclitaxel on human ovarian carcinoma xenografts in nude mice.
Hou WJ; Guan JH; Dong Q; Han YH; Zhang R
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2902-8. PubMed ID: 24254559
[TBL] [Abstract][Full Text] [Related]
19. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
20. Differential sensitivity of paclitaxel-induced apoptosis in human esophageal squamous cell carcinoma cell lines.
Faried A; Faried LS; Kimura H; Sohda M; Nakajima M; Miyazaki T; Kato H; Kanuma T; Kuwano H
Cancer Chemother Pharmacol; 2006 Feb; 57(3):301-8. PubMed ID: 16028102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
